ATC Group: M03BX02 Tizanidine

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of M03BX02 in the ATC hierarchy

Level Code Title
1 M Musculo-skeletal system
2 M03 Muscle relaxants
3 M03B Muscle relaxants, centrally acting agents
4 M03BX Other centrally acting agents
5 M03BX02 Tizanidine

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
ORAL - Oral 12 mg

Active ingredients in M03BX02

Active Ingredient Description
Tizanidine

Tizanidine is a centrally acting skeletal muscle relaxant. Polysynaptic signal transmission at spinal interneuron level, which is responsible for excessive muscle tone, is inhibited and muscle tone reduced.

Related product monographs

Title Information Source Document Type  
ZANAFLEX Tablet Health Products Regulatory Authority (IE) MPI, EU: SmPC

Medicines in this ATC group

United States (US)

Austria (AT)

Brazil (BR)

Estonia (EE)

Finland (FI)

Germany (DE)

Hong Kong (HK)

Ireland (IE)

Japan (JP)

Lithuania (LT)

Mexico (MX)

Netherlands (NL)

Nigeria (NG)

Poland (PL)

Spain (ES)

Turkey (TR)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.